All relevant data are within the paper and its Supporting Information files.

Introduction {#sec001}
============

Sarcosine, also known as *N*-methylglycine, is a non-proteinogenic imino acid occurring as an intermediate and byproduct in glycine synthesis and degradation \[[@pone.0165830.ref001]\]. In 2009, Sreekumar *et al*. delineated its potential role as urinary, non-invasive biomarker exploitable for early diagnosis of prostate cancer (PCa) \[[@pone.0165830.ref002]\]. This publication triggered sarcosine research, which resulted in a number of reports studying the connection between this low molecular mass metabolite and PCa diagnostics. Anyway, it has to be noted that the presented results have been somehow contradictory, whereas some of them have demonstrated a positive linkage only \[[@pone.0165830.ref003]--[@pone.0165830.ref005]\], while some of them have been negative \[[@pone.0165830.ref006], [@pone.0165830.ref007]\]. Thus, the further research is necessary to elucidate the role of sarcosine and its impact on properties of PCa cells.

In our initial study, we revealed that sarcosine supplementation increases the cell migration and decreases the doubling time of malignant prostatic cells *in vitro* \[[@pone.0165830.ref008]\]. Similar efforts were put by Sudhakaran and colleagues, who described that sarcosine modulates angiogenesis in endothelial cells *in vitro* through PI3K/Akt/mTOR pathway \[[@pone.0165830.ref009]\]. Moreover, Khan *et al*. demonstrated that sarcosine induces invasion and intravasation in *in vivo* PCa model \[[@pone.0165830.ref010]\]. Taken together, above mentioned studies showed sarcosine as an oncometabolite and substantiated its role in PCa progression. Although a relatively complex pool of data has been provided, to the best of our knowledge, there still exists a lack of reports on the sarcosine regulatory effects on expression of pivotal genes involved in a cell cycle and apoptosis, which lie beneath the complexity and idiopathy of each cancer \[[@pone.0165830.ref011]\].

To unravel the putative mechanisms involved in abnormal growth of cancer cells is a complex and vast task requiring powerful tools. One of them is a microarray technology, which accelerated the completion of the human genome project and eliminated numerous previous boundaries \[[@pone.0165830.ref012]\]. DNA microarrays, also called \"gene chips\" enable studying of differential gene expression using complex population of RNA \[[@pone.0165830.ref013]\]. As a result, microarrays provide large gene expression data sets for consequent data mining, which can be carried out using a number of available software applications.

Hence, in our study, we have employed a special type of DNA microarray, based on redox enzyme mediated analysis of cDNA hybridization, to give another piece to the puzzle of sarcosine oncometabolic potential. Using preclinical *in vivo* murine models (PC-3 and LNCaP xenografts); we focused on an investigation of effects of sarcosine treatment on expression of genes involved particularly in a cell cycle and apoptosis. Overall, this study reveals that sarcosine significantly up-regulates the expression of some of those genes, irrespective of androgen dependence status.

Material and Methods {#sec002}
====================

Chemicals {#sec003}
---------

Sarcosine standard and other chemicals were purchased from Sigma-Aldrich (St. Louis, MO, USA) in ACS purity, unless noted otherwise.

Cells {#sec004}
-----

The PC-3 cell line, established from a grade IV androgen-independent prostatic adenocarcinoma and the LNCaP cell line, derived from the left supraclavicular androgen-dependent lymph node PCa metastasis were purchased from the Health Protection Agency Culture Collection (Salisbury, UK). The PC-3 cells were grown in Ham's F12 medium with 7% foetal bovine serum. The LNCaP cells were grown in RPMI-1640 with 10% fetal bovine serum. Media were supplemented with penicillin (100 U/mL) and streptomycin (0.1 mg/mL). The cells were maintained at 37°C in a humidified incubator with 5% CO~2~. The treatments with sarcosine were initiated after cells reached \~70--80% confluency. Cells were then harvested and washed four times with phosphate-buffered saline (PBS, pH 7.4).

Viability (MTT) assay {#sec005}
---------------------

The suspension of 10 000 cells was added to each well of standard microtiter plates. After addition of medium (200 μL), plates were incubated for 2 days at 37°C to ensure cell growth. To determine the effects on cell viability sarcosine in concentrations 0--10 μM was applied. Plates were incubated for 24 h; then, media were removed and replaced by fresh ones, three times a day. Further, for each plate, a medium was replaced by 200 μL of fresh medium containing 50 μL of MTT (5 mg/mL in PBS) and incubated in a humidified atmosphere for 4 h at 37°C, wrapped in aluminum foil. After the incubation, MTT-containing medium was replaced by 200 μL of 99.9% dimethyl sulphoxide (*v*/*v*) to dissolve MTT-formazan crystals. Then, 25 μL of glycine buffer (pH 10.5) was added to all wells and absorbance at 570 nm was immediately determined using the Infinite 200PRO reader (Tecan, Männedorf, Switzerland).

Light microscopy {#sec006}
----------------

For light microscopy, the cells (1×10^5^ at time point 0 h) were cultivated directly on glass microscopy slides (75×25 mm, thickness 1 mm) in medium without and with 1 μM sarcosine. Prior microscopic examination, slides with a monolayer of cells were removed from Petri dishes, rinsed with a medium and PBS and directly used for investigation of their density under an inverted microscope (Olympus IX 71S8F-3, Olympus, Tokyo, Japan).

Prostate tumor xenograft models and the treatment protocol {#sec007}
----------------------------------------------------------

Twelve five-week-old male nude athymic BALB/c nu/nu mice were used for xenograft studies. PC-3 or LNCaP cells (5×10^6^) were resuspended in 100 μL of PBS with 20% Matrigel (*v*/*v*, BD Biosciences, Franklin Lakes, NJ, USA) and were then implanted subcutaneously (*s*.*c*.) into the left flank regions of the mice (six mice for PC-3 tumors and six mice for LNCaP tumors) under general anesthesia (1% Narkamon + 2% Rometar, 0.5 mL/100 g of weight). Six mice were utilized as the non-treated controls. All animals were housed in individually ventilated cages at a 12/12 h light/dark cycle and were provided *ad libitum* with standard diet and water. A tumor volume was measured twice per week following the equation (length × width^2^ × 0.5) as well as well-being of the mice. The treatment of mice was carried out *i*.*p*. two times a week for 21 days (total 6 applications) using 100 μL of 5 μM sarcosine solution. After termination by isoflurane inhalation, tumors were excised immediately and stored in RNA*later* (Thermo Fisher, Waltham, MA, USA) prior to further experiments. The use of the animals followed the European Community Guidelines as accepted principles for the use of experimental animals. The experiments were performed with the approval of the Ethics Commission at the Faculty of Medicine, Masaryk University, Brno, Czech Republic.

Histological procedures {#sec008}
-----------------------

The samples were fixed in formaldehyde (10% *v*/*v*) overnight, subsequently dehydrated in serial ethanol concentrations and embedded in paraffin. Sections were cut at 5 μm, mounted on glass slides, deparaffinized and stained with hematoxylin-eosin (H&E). The microscopic observations were conducted using an Olympus IX 71S8F-3 (Olympus, Tokyo, Japan).

Ion-exchange chromatography (IEC) {#sec009}
---------------------------------

Amino acids (glycine, serine and dimethylglycine) and sarcosine in tumor tissue were determined using IEC with Vis detection after post-column derivatization with ninhydrin (AAA-400, Ingos, Prague, Czech Republic), following conditions employed in our previous study \[[@pone.0165830.ref014]\].

Quantitation of glycine-*N*-methyltransferase (GNMT) and sarcosine dehydrogenase (SARDH) {#sec010}
----------------------------------------------------------------------------------------

Amounts of GNMT and SARDH in sarcosine treated and non-treated tumors were quantified by human sandwich ELISA kits with HRP-conjugated secondary antibody and [3,3\',5,5\'-tetramethylbenzidine](https://en.wikipedia.org/wiki/3,3′,5,5′-Tetramethylbenzidine) (TMB) as a substrate (LSBio, Seattle, WA, USA). Color intensity at 495 nm was read in a VersaMax microplate reader (Molecular Devices, Sunnyvale, CA, USA).

Isolation of RNA and reverse transcription (RT) {#sec011}
-----------------------------------------------

High pure total-RNA isolation kit (Roche, Basel, Switzerland) was used for an isolation of tissue RNA. The medium was removed and samples were twice washed with 5 mL of ice-cold PBS. Cells were scraped off, transferred to clean tubes and centrifuged at 20 800×*g* for 5 min at 4°C. After that, lysis buffer was added and RNA isolation was carried out according to manufacturer\'s instructions. Isolated RNA was used for cDNA synthesis. RNA (500 ng) was transcribed using transcriptor first strand cDNA synthesis kit (Roche) according to manufacturer\'s instructions. Prepared cDNA (20 μL) was diluted with RNase-free water to a total volume of 100 μL and 5 μL of this solution was employed for microarray analyses.

Electrochemical microarray {#sec012}
--------------------------

cDNA was biotinylated on its 3' end using the Biotin 3' End DNA Labeling Kit (Thermo Scientific, Waltham, MA, USA) following the manufacturer's instructions. The microarray was performed as previously described by Roth *et al*. \[[@pone.0165830.ref015]\]. For hybridization, Human Cancer 3711 ElectraSense medium density 4×2k array slides with 1,609 DNA probes (Custom Array, Bothell, WA, USA), were firstly pre-hybridized for 30 min at 50°C using 6× SSPE (0.9 M NaCl, 60 mM sodium phosphate, 6 mM EDTA), 5× Denhardt´s solution and sonicated salmon sperm DNA (100 μg/mL). Then, hybridization of biotin-labeled cDNA was performed at 50°C for 18 h in 6× SSPE and salmon sperm DNA (100 μg/mL). Array chips were rinsed with low ionic strength 3× SSPET (3× SSPE, 0.05% Tween-20) and PBST (2× phosphate-buffered saline, pH 7.4, 0.1% Tween-20) to remove weakly bound DNA. Subsequently, array chips were blocked with biotin blocking solution for 15 min. Chips were then incubated for 30 min with poly-horseradish peroxidase-streptavidin (1:1,000 in PBS containing 1% bovine serum albumin and 0.05% Tween-20). Next, chips were rinsed three times with biotin wash solution and TMB rinse solution, followed by incubation with TMB substrate. Measurements were performed using the ElectraSense detection kit (Custom Array). All post-hybridization processing steps were performed at 25°C.

Semi-quantitative RT-PCR for validation of selected genes {#sec013}
---------------------------------------------------------

To confirm selected microarray results we separately performed semi-quantitative RT-PCR (SQ-RT-PCR) of genes with the expression 2.5-fold stronger than non-treated individuals. To adjust the amount of transcribed cDNA, *β-actin* was selected as an internal control. The primer sequences were as follows: 5´-TCCATCGTCCACAGAAAG-3´ (forward) and 5´-AAATGTCCTCCGCAAGCT-3´ (reverse). For designing the primers of tested genes, the sequence information was collected from the NCBI GenBank ([www.ncbi.nih.gov](http://www.ncbi.nih.gov/)). Information about the PCR primers is available upon request to the corresponding author. SQ-RT-PCR experiments were performed in conditions described in our previous study \[[@pone.0165830.ref016]\]. For evaluation of differences in gene expression between sarcosine treatment and non-treated controls, 10 μL of each SQ-RT-PCR product was electrophoresed on a 2.0% agarose gel and stained with ethidium bromide.

Descriptive statistics and exploited bioinformatical tools {#sec014}
----------------------------------------------------------

For the statistical evaluation of the results, the mean was taken as the measurement of the main tendency, while standard deviation was taken as the dispersion measurement. Differences between groups were analyzed using paired *t*-test and ANOVA. Unless noted otherwise, the threshold for significance was *p* \< 0.05. For analyses Software Statistica 12 (StatSoft, Tulsa, OK, USA) was employed. The annotation analyses were performed using the GoMiner (<http://discover.nci.nih.gov/gominer/index.jsp>), interactome network was constructed using the STRING software (<http://string-db.org/>) and the PCa metabolic pathway was visualized using Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway database (<http://www.genome.jp/kegg/>), which provides gold standard sets of molecular pathways. The involvement of genes involved in a cell cycle was carried out using the Reactome ([www.reactome.org](http://www.reactome.org/)).

Results {#sec015}
=======

Effect of sarcosine on PC-3 cells viability and proliferation *in vitro* {#sec016}
------------------------------------------------------------------------

In the first step, we considered pivotal to determine the sarcosine effects on the PC-3 and LNCaP cells viability *in vitro*. [Fig 1Aa](#pone.0165830.g001){ref-type="fig"} illustrates that even the lowest applied sarcosine supplementation stimulated the growth of PC-3 cells after 24 h. Noteworthy, the plateau of the stimulation effects was reached using approx. 0.2 μM sarcosine and higher concentrations resulted in slow decreasing viability trends. Similarly, sarcosine treatment stimulated the proliferation of LNCaP cells, but the stimulatory effects were significantly lower than those found in PC-3 cells ([Fig 1Ab](#pone.0165830.g001){ref-type="fig"}). As there were obvious impacts on a growth rate of cells, we further analyzed sarcosine influence on their confluency. Light microscopy photographs in [Fig 1Ba and 1Bb](#pone.0165830.g001){ref-type="fig"} show that sarcosine supplementation stimulates the proliferation of both PC-3 and LNCaP cells, which can be observed as the increased density of these cells after 72 h cultivation. The found *in vitro* data led us to further proceed to *in vivo* experiments utilizing murine PC-3 and LNCaP xenografts focusing on the effects of sarcosine treatment on a tumor growth and gene expression profiles related to repeated sarcosine supplementation.

![*In vitro* supplementation of PCa cells with sarcosine.\
(**A**) Viability (MTT) assay showing the trend in (**Aa**) PC-3 and (**Ab**) LNCaP cells growth under 24 h supplementation with sarcosine (0--10 μM). Values are expressed as the means ± standard deviations of six independent replicates (*n* = 6). (**B**) Micrographs of densities of (**Ba**) PC-3 cultivated in standard Ham's F12 medium (*left*) and in Ham's F12 medium enriched for 1 μM sarcosine (*right*) and (**Bb**) LNCaP cultivated in RPMI-1640 medium (*left*) and in RPMI-1640 medium enriched for 1 μM sarcosine (*right*). The length of scale bar is 500 μm.](pone.0165830.g001){#pone.0165830.g001}

Sarcosine treatment effects on growth of tumors *in vivo* {#sec017}
---------------------------------------------------------

Murine xenografts were induced by using *s*.*c*. inoculation of PCa cells. The experimental workflow of the *in vivo* experiment, showing the treatment course, termination and subsequent analyses is depicted in **[Fig 2A](#pone.0165830.g002){ref-type="fig"}**. The results obtained by weighing the treated and non-treated mice demonstrate that in both cases, sarcosine induced significant losses of weight when compared to non-treated individuals \[*p* \< 0.05, ([Fig 2B](#pone.0165830.g002){ref-type="fig"})\]. No mice died or had to be euthanized before the endpoint of the experiment. After the termination, considerable differences between the sizes of excised ectopic prostate tumors were found ([Fig 2C](#pone.0165830.g002){ref-type="fig"}), as well as the significant differences in the tumor weights \[175 mg *vs*. 94 mg for PC-3 and 137 mg *vs*. 90 mg for LNCaP, *p* \< 0.05 ([Fig 2D](#pone.0165830.g002){ref-type="fig"})\]. The histological examination of tumor sections however did not reveal any changes within them ([Fig 2E](#pone.0165830.g002){ref-type="fig"}).

![The murine PC-3 and LNCaP xenografts were treated with sarcosine *i*.*p*.\
(**A**) Schematic depiction of experimental workflow beginning with the PCa cells (5×10^6^) *s*.*c*. inoculation. (**B**) Average weight of mice determined after the termination of experiment. (**C**) Selected photographs of excised ectopic prostate tumors treated with sarcosine (*left*) and non-treated after termination of the experiment (*right*). (**D**) Average tumor weight at the endpoint of the experiment. Values are expressed as the means ± standard deviations of three independent replicates (*n* = 3). Vertical bars indicate standard error. Asterisks indicate significant differences (*p* \< 0.05) compared to the untreated group. (**E**) H&E-stained tissue sections of ectopic prostate tumors after treatment with sarcosine (*left*) and non-treated (*right*). The length of scale bar is 100 μm.](pone.0165830.g002){#pone.0165830.g002}

Sarcosine treatment effect on concentration of sarcosine pathway-related amino acids in tumors {#sec018}
----------------------------------------------------------------------------------------------

As sarcosine pathway involves amino acids providing the essential precursors for the synthesis of proteins, lipids and nucleic acids (particularly serine and glycine), we tested the influence of sarcosine treatment on their tumor tissue concentrations. We also included dimethylglycine (Dmg), the amino acid that can be demethylated by dimethylglycine dehydrogenase to form sarcosine (schematic depiction is shown in [Fig 3A](#pone.0165830.g003){ref-type="fig"}). The results found indicate that in PC-3 xenografts, sarcosine treatment resulted in significant (*p* \< 0.05) increase in glycine and serine levels ([Fig 3B](#pone.0165830.g003){ref-type="fig"}). Moreover, we also detected increased concentrations of sarcosine (0.65 nmol of sarcosine per mg of treated tumor tissue *vs*. 0.43 nmol of sarcosine per mg of non-treated tumor) there. On the other hand, the amount of Dmg was not significantly affected by the sarcosine treatment.

![Effect of sarcosine treatment on the tumor tissue concentrations of sarcosine pathway-related amino acids.\
(**A**) Schematic depiction showing the sarcosine pathway ongoing in mitochondrion. Red rectangles highlight the amino acids, whose tissue levels were increased due to sarcosine treatment. Dmg-Dimethylglycine, Gly-Glycine, Ser-Serine, DMGHD-Dimethylglycine dehydrogenase, SARDH-Sarcosine dehydrogenase, GNMT-Glycine-*N*-methyltransferase, GDC-Glycine decarboxylase, SHMT-Serine hydroxymethyltransferase, THF-Tetrahydrofolate, 10f-THF-10-Formyltetrahydrofolate, CH~2~-THF-Methylenetetrahydro-folate, FDH-Formyltetrahydrofolate dehydrogenase, FTS-Formyltetrahydrofolate synthase. Bar graphs showing the differences in tumor tissue Sar, Gly, Dmg and Ser levels in sarcosine treated and non-treated (**B**) PC-3 and (**C**) LNCaP mice. The levels of GNMT and SARDH were estimated in (**D**) PC-3 and (**E**) LNCaP mice by ELISA. Values are means ± standard deviations of three independent replicates (*n* = 3). Asterisks indicate significant differences (\*, *p* \< 0.05) or (\*\*, *p* \< 0.01) compared to the untreated group.](pone.0165830.g003){#pone.0165830.g003}

Moreover, [Fig 3C](#pone.0165830.g003){ref-type="fig"} demonstrates that LNCaP tumors exhibited very similar response to the sarcosine treatment, having lower initial and induced concentration of sarcosine (0.33 nmol of sarcosine per mg of treated tumor tissue *vs*. 0.19 nmol of sarcosine per mg of non-treated tumor). As GNMT and SARDH are the major enzymes involved in sarcosine metabolism, we further analyzed their amounts within the tumor tissue. [Fig 3C and 3D](#pone.0165830.g003){ref-type="fig"} show that sarcosine treatment resulted in significant (*p* \< 0.05) increase in concentration of SARDH, which catalyzes sarcosine-to-glycine conversion. In case of GNMT we identified only negligible effects on its amount after sarcosine treatment in both tumor tissues.

Sarcosine effects on gene expression profiling in tumors {#sec019}
--------------------------------------------------------

The tumors were further used for isolation of RNA, subsequent reverse transcription and electrochemical microarray profiling (representative microarray heatmaps for the treated and non-treated PC-3 and LNCaP tumors are shown in [S1 Fig](#pone.0165830.s001){ref-type="supplementary-material"}. [Table 1](#pone.0165830.t001){ref-type="table"} and [Table 2](#pone.0165830.t002){ref-type="table"} show the lists of genes (*n* = 43 for PC-3 and *n* = 50 for LNCaP), along with their accession numbers, which were found up-regulated in six independent analyses (*n* = 6). As a threshold for up-regulation, medians, whose fold ratio was ≥ 1.5 compared to non-treated xenografts were exploited. Microarray analyses revealed also seven genes in PC-3 and four genes in LNCaP tumors, which could be classified as down-regulated; however, in both types of cells, none of them reached threshold expression ≤ 1.5 ([S1 Table](#pone.0165830.s002){ref-type="supplementary-material"}). Thus, they were not considered for further analyses. The complete list of up-regulated genes served as input for further bioinformatical analyses.

10.1371/journal.pone.0165830.t001

###### List of genes up-regulated in PC-3 xenografts in a response to sarcosine treatment (genes with the median fold ratio ≥ 1.5 are shown).

![](pone.0165830.t001){#pone.0165830.t001g}

  Accession No.   Gene name                                           Symbol       Fold ratio   *p-*value
  --------------- --------------------------------------------------- ------------ ------------ -----------
  NM_001071       Thymidylate synthetase                              *TYMS*       4.2          0.0016
  NM_001323304    Aurora kinase A                                     *AURKA*      3.7          0.0041
  NM_006101       Kinetochore associated 2                            *KNTC2*      3.5          0.0012
  NM_053056       Cyclin D1                                           *CCND1*      3.4          0.0004
  NM_006469       Influenza virus NS1A binding protein                *IVNS1ABP*   3.1          0.0023
  NM_001278547    Mitogen-activated protein kinase 8                  *MAPK8*      3.0          0.0067
  NM_001302961    Kallikrein 4                                        *KLK4*       3.0          0.0066
  NM_001315       Mitogen-activated protein kinase 14                 *MAPK14*     2.6          0.0011
  NM_000044       Androgen receptor                                   *AR*         2.6          0.0024
  NM_001030047    Prostate-specific antigen                           *KLK3*       2.5          0.0090
  NM_001256339    Homeobox protein NK-3 homology A                    *NKX3-1*     2.2          0.0016
  NM_001281741    Ubiquitin-conjugating enzyme E2C                    *UBE2C*      2.2          0.0000
  NM_012094       Peroxiredoxin 5                                     *PRDX5*      2.2          0.0015
  NM_001276464    Nuclear receptor subfamily 5, group A               *NR5A2*      2.0          0.0068
  NM_001179425    Ribophorin II                                       *RPN2*       2.0          0.0097
  NM_003681       Pyridoxal kinase                                    *PDXK*       1.9          0.0087
  NM_001005915    V-erb-b2 viral oncogene                             *ERBB3*      1.9          0.0020
  NM_015286       Synemin                                             *SYNM*       1.9          0.0009
  NM_002228       Jun proto-oncogene                                  *JUN*        1.9          0.0082
  NM_001012505    Forkhead box P1                                     *FOXP1*      1.8          0.0036
  NM_001137559    Anaphase promoting complex subunit 5                *ANAPC5*     1.8          0.0030
  NM_001291715    Preferentially expressed antigen in melanoma        *PRAME*      1.8          0.0005
  NM_006571       Cyclin-dependent kinase inhibitor 1B                *p27*        1.8          0.0012
  NM_175620       Metallothionein M                                   *MTM*        1.7          0.0003
  NM_001199149    Lactotransferrin                                    *LTF*        1.7          0.0012
  NM_005494       DnaJ homology, subfamily B, member 6                *DNAJB6*     1.7          0.0082
  NM_001077500    Kallikrein 10                                       *KLK10*      1.7          0.0085
  NM_000918       Procollagen-proline, 2-oxoglutarate 4-dioxygenase   *P4HB*       1.7          0.0075
  NM_001007226    Speckle-type POZ protein                            *SPOP*       1.7          0.0003
  NM_001098209    T-cell factor/lymphoid enhancer factor              *TCF/LEF*    1.7          0.0062
  NM_000314       Phosphatase and tensin homolog                      *PTEN*       1.7          0.0027
  NM_002675       Promyelocytic leukemia                              *PML*        1.7          0.0023
  NM_001291309    Proprotein convertase subtilisin/kexin type 6       *PCSK6*      1.7          0.0033
  NM_003183       ADAM metallopeptidase domain 17                     *ADAM17*     1.7          0.0003
  NM_006191       Proliferation-associated 2G4                        *PA2G4*      1.7          0.0005
  NM_005066       Splicing factor proline/glutamine-rich              *SFPQ*       1.6          0.0048
  NM_001291428    Bcl2-associated X protein                           *BAX*        1.6          0.0081
  NM_002965       S100 calcium-binding protein A9                     *S100A9*     1.6          0.0009
  NM_001300960    Cyclin-dependent kinase 19                          *CDK19*      1.6          0.0044
  NM_006763       BTG family member 2                                 *BTG2*       1.5          0.0066
  NM_006275       Serine/arginine-rich splicing factor 6              *SRSF6*      1.5          0.0023
  NM_007203       Paralemmin 2                                        *PALM2*      1.5          0.0041
  NM_001134851    Transcription factor 7                              *TCF7*       1.5          0.0025

10.1371/journal.pone.0165830.t002

###### List of genes up-regulated in LNCaP xenografts in a response to sarcosine treatment (genes with the median fold ratio ≥ 1.5 are shown).

![](pone.0165830.t002){#pone.0165830.t002g}

  Accession No.   Gene name                                           Symbol      Fold ratio   *p*-value
  --------------- --------------------------------------------------- ----------- ------------ -----------
  NM_003981       Reticulocalbin 1                                    *RCN1*      10.0         0.0071
  NM_002901       Nuclear receptor subfamily 4, group A, member 3     *NR4A3*     6.6          0.0005
  NM_000044       Androgen receptor                                   *AR*        6.1          0.0001
  NM_022002       Breast cancer 1, early onset                        *BRCA1*     5.5          0.0069
  NM_006191       Proliferation-associated 2G4                        *PA2G4*     4.7          0.0042
  NM_006571       Cyclin-dependent kinase inhibitor 1B                *p27*       4.1          0.0060
  NM_003724       Programmed cell death 2                             *PDCD2*     3.9          0.0003
  NM_000295       SRY (sex determining region Y)-box 2                *SOX2*      3.7          0.0001
  NM_001291715    Preferentially expressed antigen in melanoma        *PRAME*     3.7          0.0087
  NM_005033       Procollagen-proline, 2-oxoglutarate 4-dioxygenase   *P4HB*      3.3          0.0036
  NM_001302961    Kallikrein 4                                        *KLK4*      3.1          0.0001
  NM_001005915    V-erb-b2 viral oncogene                             *ERBB3*     3.1          0.0095
  NM_012142       X-box binding protein 1                             *XBP1*      2.5          0.0037
  NM_005494       DnaJ homology, subfamily B, member 6                *DNAJB6*    2.4          0.0005
  NM_004911       Proliferating cell nuclear antigen                  *PCNA*      2.4          0.0025
  NM_006516       Nuclear factor of kappa light gene inhibitor        *NFKBIA*    2.4          0.0004
  NM_001256339    Homeobox protein NK-3 homology A                    *NKX3-1*    2.4          0.0063
  NM_001005909    B-cell lymphoma 6                                   *BCL6*      2.3          0.0011
  NM_001071       Thymidylate synthetase                              *TYMS*      2.3          0.0007
  NM_002598       SRY (sex determining region Y)-box 4                *SOX4*      2.3          0.0040
  NM_016221       Interleukin 6 (interferon, beta 2)                  *IL6*       2.3          0.0000
  NM_015927       Nuclear receptor subfamily 4, group A, member 3     *NR4A3*     2.3          0.0033
  NM_000314       Phosphatase and tensin homolog                      *PTEN*      2.3          0.0014
  NM_173158       E2F transcription factor 4                          *E2F4*      2.2          0.0040
  NM_138320       Asparagine synthetase                               *ASNS*      2.2          0.0010
  NM_001098209    T-cell factor/lymphoid enhancer factor              *TCF/LEF*   2.1          0.0030
  NM_006852       Ubiquitin-conjugating enzyme E2C                    *UBE2C*     2.0          0.0036
  NM_001137559    Anaphase promoting complex subunit 5                *ANAPC5*    2.0          0.0027
  NM_182790       BCL2-associated X protein                           *BAX*       2.0          0.0044
  NM_000434       Primase, polypeptide 2A                             *PRIM2A*    2.0          0.0009
  NM_002916       Cathepsin C                                         *CTSC*      1.9          0.0090
  NM_000158       Mitogen-activated protein kinase 7                  *MAPK7*     1.9          0.0082
  NM_012296       Transforming growth factor, beta 3                  *TGFB3*     1.9          0.0010
  NM_001030047    Prostate-specific antigen                           *KLK3*      1.8          0.0022
  NM_015286       Synemin                                             *SYNM*      1.8          0.0011
  NM_015286       Kallikrein 10                                       *KLK10*     1.8          0.0024
  NM_001122       Mitogen-activated protein kinase 10                 *MAPK10*    1.8          0.0081
  NM_006681       Growth arrest-specific 6                            *GAS6*      1.8          0.0006
  NM_001001567    ADAM metallopeptidase domain 17                     *ADAM17*    1.8          0.0009
  NM_007106       Cyclin D2                                           *CCND2*     1.7          0.0020
  NM_004528       BCL2-related protein A1                             *BCL2A1*    1.7          0.0071
  NM_001470       Splicing factor proline/glutamine-rich              *SFPQ*      1.7          0.0087
  NM_138609       Cas-Br-M ecotropic retroviral sequence              *CBL*       1.6          0.0097
  NM_004290       Protein kinase, cAMP dependent                      *PRKACB*    1.6          0.0067
  NM_022805       TIMP metallopeptidase inhibitor 1                   *TIMP1*     1.6          0.0015
  NM_016237       Replication factor C                                *RFC4*      1.6          0.0087
  NM_020738       Protein kinase C, beta 1                            *PRKCB1*    1.5          0.0068
  NM_000593       Transcription factor 7 (T-cell specific, HMG-box)   *TCF7*      1.5          0.0011
  NM_003290       Integrin, beta 5                                    *ITGB5*     1.5          0.0039
  NM_014573       Proteasome (prosome, macropain) subunit             *PSMD2*     1.5          0.0098

SQ-RT-PCR validation of microarray data {#sec020}
---------------------------------------

Overall, our microarray analyses revealed 18 overlapping genes, which were up-regulated in both tested PCa cell lines as the response to sarcosine treatment ([Fig 4A](#pone.0165830.g004){ref-type="fig"}). To validate the microarray results, we performed SQ-RT-PCR analyses using the sarcosine treated and non-treated tumors and evaluated gene expression after normalization according to the expression of *β-actin*. [Fig 4B](#pone.0165830.g004){ref-type="fig"} shows the SQ-RT-PCR results for the most up-regulated genes, which were selected for validation (up-regulation fold ratio ≥ 2.5). Noteworthy, all of the results corroborated our microarray analyses and confirmed the considerable influence on genes expression caused by sarcosine administration.

![Comparison of gene expression in PC-3 and LNCaP xenografts.\
(**A**) Venn diagram showing the number of overlapping genes up-regulated after treatment of PC-3 and LNCaP cells with sarcosine. (**B**) SQ-RT-PCR validation of 10 selected genes up-regulated in murine PC-3 and LNCaP xenografts after sarcosine treatment (up-regulation ≥ 2.5). Expression of *β-actin* constituted as loading control. Lanes **1**--**3**---RNA isolated from sarcosine treated mice, lane **4**--**6**---RNA isolated from non-treated mice.](pone.0165830.g004){#pone.0165830.g004}

Classification of biological roles of genes influenced by sarcosine treatment {#sec021}
-----------------------------------------------------------------------------

To evaluate biological relevance of the differentially expressed genes in sarcosine treated and non-treated prostate tumors, we carried out an annotation analysis, which identifies the involvement of particular genes within biological processes. For both types of PCa cells xenografts, the up-regulated gene set was found to mostly include the genes belonging to \"metabolic process\", \"cellular process\", \"biological regulation\", \"response to stimulus\", \"developmental process\", \"apoptotic process\" and others ([Table 3](#pone.0165830.t003){ref-type="table"}). Taken together this analysis provided a preliminary insight into the function of genes that are up-regulated as a response to sarcosine treatment.

10.1371/journal.pone.0165830.t003

###### Percentage of genes up-regulated in ectopic prostate xenografts treated with sarcosine classified with respect to their biological functions.

![](pone.0165830.t003){#pone.0165830.t003g}

                                                  PC-3   LNCaP
  ----------------------------------------------- ------ -------
  Metabolic process                               55.8   52.0
  Cellular process                                44.2   51.5
  Biological regulation                           26.7   36.5
  Response to stimulus                            20.0   15.5
  Developmental process                           20.0   14.8
  Apoptotic process                               15.8   23.2
  Multicellular organism process                  10.8   26.1
  Cellular component organization or biogenesis   5.8    10.1
  Reproduction                                    5.8    3.1
  Immune system process                           5.0    4.2
  Locomotion                                      2.5    1.1
  Biological adhesion                             2.5    2.0

Further, to prioritize the differentially expressed genes involved in the apoptosis and cell cycle, which are the major hallmarks of each type of cancer, we utilized STRING database of known and predicted interactions. [Fig 5](#pone.0165830.g005){ref-type="fig"} illustrates the interactome network, where the red nodes highlight the genes from our up-regulated set, whose expression is stimulated by sarcosine treatment and which may be involved in a cell death of PC-3 cells (namely *FOXP1*, *LTF1*, *TCF7*, *DNAJB6*, *JUN*, *MAPK8*, *ERBB3*, *BTG2*, *AURKA*, *PA2G4*, *PML*, *PRDX5*, *PRAME* and *IVNS1ABP*) and LNCaP cells (namely *ITGA6*, *BRCA1*, *CBL*, *ERBB3*, *PA2G4*, *KLF4*, *MAPK7*, *ASNS*, *SOX4*, *TCF7*, *NR4A3*, *TGFB3*, *GAS6*, *TIMP1*, *BAX*, *BCL2A1*, *NFKBIA*, *HSP9OB1*, *DNAJB6*, *XBP1*, *BCL6* and *PRAME*). Noteworthy, *TCF7*, *DNAJB6*, *ERBB3* and *PRAME* were up-regulated in both types of cells pointing out their importance for cell cycle and apoptosis of metastatic PCa cells.

![Interactome network showing the genes, which were up-regulated after sarcosine treatment and which are fundamental for apoptosis and cell cycle (PC-3 on the left, LNCaP on the right).\
The red nodes highlight the genes, which were up-regulated and are involved in negative regulation of a cell death. The interior of the circle represents the structure of proteins. The color of the line provides evidence of the different interactions among proteins. A red line indicates the presence of fusion evidence; a green line, neighborhood evidence; a blue line, concurrence evidence; a purple line, experimental evidence; a light blue line, database evidence; a black line, coexpression evidence. The genes were analyzed using STRING software (version 10.0).](pone.0165830.g005){#pone.0165830.g005}

Sarcosine and induction of genes involved in PCa-specific metabolic pathway and cell cycle {#sec022}
------------------------------------------------------------------------------------------

Further, we analyzed the expression changes associated with the PCa biochemical pathway defined in the KEGG database \[[@pone.0165830.ref017]\]. It is worth noting that KEGG pathway maps are an abbreviated representation of known interactions, focusing on those considered being the best supported by the evidence and relevance. [Fig 6](#pone.0165830.g006){ref-type="fig"} and [Fig 7](#pone.0165830.g007){ref-type="fig"} show the PCa metabolic pathway-specific KEGG diagrams, where the up-regulated genes are highlighted in red. Noteworthy, these genes are involved in the most fundamental processes, such as the cell proliferation and survival \[*TCF/LEF*, *KLK3* (or *PSA*)\], cell cycle and its progression (*p27*), PI3K/Akt signaling pathway (*NKX3*.*1* and *PTEN*) and hormone signaling (*AR*). The diagrams underscore that in both metastatic PCa cells, sarcosine affects nearly the same targets involved in fundamental metabolic processes. [Fig 8](#pone.0165830.g008){ref-type="fig"} demonstrates a general cell cycle and the phases of mitosis. This detailed insight into the specific effects of sarcosine treatment revealed that in PC-3 tumors, sarcosine up-regulates genes, which are vital for a cell cycle, such as *RPN2* involved in all cell cycle phases, *UBE2C* involved in S phase and M phase (specifically prometaphase and anaphase), *KNTC2* and *ANAPC5* involved in S and M phases, *TYMS* and *CCND1* involved in G~1~-G~1~/S phases and *SYNM* involved in G~2~-G~2~/M phases. [Fig 8](#pone.0165830.g008){ref-type="fig"} illustrates that similarly, in LNCaP tumors, sarcosine affects a cell cycle. Remarkably, up-regulation of *ANAPC5*, *SYNM* and *UBEC2C* and *TYMS* was identified within both tumor tissues exposed to sarcosine, irrespective of androgen dependence. Overall, the sarcosine-induced up-regulation of cell cycle controlling genes is likely one of the factor standing behind the sarcosine treatment-stimulated PCa cells proliferation and tumor growth.

![KEGG PCa-specific metabolism diagram for PC-3 cells.\
Gene expression shifts are projected as comparison of sarcosine treated and non-treated prostate tumors. The genes highlighted in red were found up-regulated after the sarcosine treatment in both PCa xenografts. The pathway map is species-specific (*Homo sapiens*).](pone.0165830.g006){#pone.0165830.g006}

![KEGG PCa-specific metabolism diagram for LNCaP cells.\
Gene expression shifts are projected as comparison of sarcosine treated and non-treated prostate tumors. The genes highlighted in red were found up-regulated after the sarcosine treatment in both PCa xenografts. The pathway map is species-specific (*Homo sapiens*).](pone.0165830.g007){#pone.0165830.g007}

![Schematic depiction of cell cycle and illustration of genes, which induce progression of cell cycle, performed using the Reactome software.\
Black frames indicate the genes, which were up-regulated after sarcosine treatment.](pone.0165830.g008){#pone.0165830.g008}

Discussion {#sec023}
==========

PCa remains a leading cause of illness and death among men in the US and Western Europe. The optimal course of treatment for a given individual is often uncertain. Recent metabolomic studies have identified various oncometabolites of PCa that could be likely associated with aggressive disease \[[@pone.0165830.ref002], [@pone.0165830.ref018], [@pone.0165830.ref019]\]. However, an understanding the biological actions of these molecules is anticipated to provide valuable information that can be helpful not only for enhancement of diagnostic and prognostic possibilities, but also for the development of novel biological treatment agents.

Numerous studies highlighted the significance of sarcosine as oncometabolite in PCa progression \[[@pone.0165830.ref002]--[@pone.0165830.ref004], [@pone.0165830.ref010]\]. Previously, we showed that sarcosine supplementation stimulates the cell proliferation and decreased the time required for cell division in malignant (22Rv1) and metastatic (PC-3) PCa cells \[[@pone.0165830.ref008]\]. In the present work we show that sarcosine exhibits considerable stimulatory effects on growth of PC-3 and LNCaP cells, even at very low concentrations, which are comparable to those found in urinary specimens of subjects suffering from aggressive PCa \[[@pone.0165830.ref003]\]. Similar efforts were put by Khan and coworkers using benign DU145 prostate cells as it was found that sarcosine did not affect their ability to progress through the cell cycle or impair cell proliferation \[[@pone.0165830.ref010]\]. Thus, these findings, which are in good agreement with ours, highlight the particular importance of sarcosine in malignant/metastatic prostate cells.

Despite that an utilization of *in vivo* preclinical model is critical for complex understanding of the actions triggered by sarcosine treatment, we established a system that mimics the tumor biology and its microenvironment by using xenografts. Sarcosine treatment of PC-3 and LNCaP xenografts resulted in a significant decrease (*p* ˂ 0.05) in weight of treated mice, concomitantly with the increased size of their tumors. This indicates the stimulation of cancer progression with simultaneous deterioration of the conditions of treated animals. Previously, it has been demonstrated that stable overexpression of the SARDH enzyme or knock-down of the GNMT enzyme led to inhibition of the growth of PCa xenografts \[[@pone.0165830.ref010]\]. Nevertheless, the effect of direct sarcosine supplementation was not investigated. Hence, in this work, we provide further evidence of the stimulatory effects of sarcosine on a model of androgen dependent (LNCaP) and androgen independent (PC-3) metastatic PCa, which was firstly studied on a level of the impact on free amino acids and enzymes, which are involved in sarcosine biosynthesis and/or conversion schematized in [Fig 3A](#pone.0165830.g003){ref-type="fig"}.

Moreover, our results revealed sarcosine-induced increase of glycine and serine within the tumor mass formed by both types of PCa cells. In general, cancer cells undergo specific metabolic reprogramming to sustain cell growth and proliferation \[[@pone.0165830.ref020]\]. In addition to a large energy requirement, they tend to accumulate building blocks for the construction of new cellular components including nucleic acids, proteins, and lipids, as well as important cofactors for the maintenance of the cellular redox status \[[@pone.0165830.ref021]\]. The importance of serine and glycine as precursors in those processes is comprehensively summarized in the review by Amelio and coworkers \[[@pone.0165830.ref022]\]. Briefly, both serine and glycine contribute to cellular metabolism through the glycine cleavage system, which refuels one-carbon metabolism based on chemical reactions of folate compounds \[[@pone.0165830.ref023]\]. The importance of folate metabolism is underlined by the fact that antifolate chemotherapy is currently widely used in cancer treatment \[[@pone.0165830.ref024]\]. Similarly to serine and glycine, we also identified significantly higher amount of sarcosine, but not its precursor---dimethylglycine. Sarcosine likely accumulates within the tumor mass with the consequent increase in serine and glycine, which act as the tumor growth promoters. As it was evidenced, sarcosine increased amount also stimulates the SARDH expression. Although there is a lack of direct evidence of linkage between SARDH and PCa aggressiveness, Yoon and coworkers demonstrated that the expression of SARDH is associated with shorter overall survival of subjects suffering from luminal A type breast cancer \[[@pone.0165830.ref025]\]. Although here we report obvious effects of sarcosine treatment on its pathway *in vivo*, further analysis of metabolic activities of sarcosine associated enzymes might be done to shed more light into this phenomenon.

As another level of regulation, we further investigated the differential gene expression sets related to sarcosine treatment. Particularly, we exploited electrochemical DNA microarrays, which are designated to analyze 2000 genes, involved in any aspect of cancer disease. Such approach provides a complex insight into the expression of genes that are involved in regulation of cell cycle and apoptosis, which are the major hallmarks of cancer \[[@pone.0165830.ref011]\]. Within the set of the identified differentially expressed genes, we found significant up-regulation of genes involved in a regulation of cell cycle and genes stimulating cell proliferation. Interestingly, in both types of PCa cells, we also identified sarcosine-related up-regulation of gene encoding androgen receptor (AR), which is a transcription factor mediating the transcription of both SARDH and GNMT \[[@pone.0165830.ref026]\].

TYMS enzyme (encoded by *TYMS*) plays a role in DNA synthesis and G~1~-S transition. Its expression is higher in neoplastic than in normal prostate epithelium and was shown to be tightly linked to high GS, pathological tumor stage and early PSA recurrence (*p* \< 0.0001) \[[@pone.0165830.ref027]\]. Noteworthy, TYMS protein is important target for 5-fluorouracil (5-FU) treatment, however this drug has only limited response rates in PCa \[[@pone.0165830.ref028]\]. Our findings encourage further studies to compare the expression of TYMS and amounts of urinary sarcosine, which can be exploited as non-invasive predictor of success of 5-FU chemotherapy.

Similarly, *AURKA* gene amplification has been documented in 67% of neuroendocrine PCa, which progress to highly aggressive variants \[[@pone.0165830.ref029]\]. *CCND1* overexpression accounts for cisplatin resistance through cell cycle control and inhibits cellular apoptosis pathway in the most of tumors \[[@pone.0165830.ref030]\]. Overexpression of *KLK4* was observed in patients with high T stage and GS \[[@pone.0165830.ref031]\] and *KLK3* encodes PSA, a widely used biomarker for PCa detection and disease monitoring \[[@pone.0165830.ref032]\]. *KNTC2* encodes the Hec1 protein, which plays an essential role in chromosome segregation by interacting through its coiled-coil domains with several proteins modulating the G~2~/M transition \[[@pone.0165830.ref033]\]. Hec1 is a critical modulator of mitosis, highly expressed in most cancer cells, including PCa \[[@pone.0165830.ref034]\], however in this case the comparison of their expression with sarcosine amounts was not carried out, too.

In LNCaP tumors, we found that the most up-regulated gene was *RCN1*; encoding the homonymous protein RCN1, which has been identified as surface adhesion molecule that might participate in metastasis of PCa \[[@pone.0165830.ref035]\]. *NR4A3* is a member of the orphan nuclear receptor family referred to as NR4A. These receptors have been implicated in cell cycle regulation, apoptosis and carcinogenesis \[[@pone.0165830.ref036]\]. As it has been found that *NR4A3* controls both, survival and cell death of cancer cells, it is worth noting that sarcosine significantly stimulates its up-regulation, which can be one of the mechanisms of PCa proliferation.

In both types of PCa xenografts, we have revealed that sarcosine treatment stimulated the expression of AR, whose activity was intimately linked to PCa. Kim *et al*. show that AR and sarcosine metabolism-related enzymes have significant relationships with each other \[[@pone.0165830.ref037]\] and androgens can increase GNMT expression through AR binding the androgen response element existing on the first exon coding region of *GNMT*. Similarly, Sreekumar and coworkers indicated that AR appears to directly regulate sarcosine levels *via* transcriptional control of its regulatory enzymes \[[@pone.0165830.ref002]\]. Nevertheless, the principle of the *vice versa* mechanism (sarcosine stimulation of AR expression) needs to be clarified. Recently, it was demonstrated that exogenous addition of sarcosine to LNCaP cells *in vitro* caused negligible stimulation of AR expression only \[[@pone.0165830.ref038]\]. Discrepancy in our results is likely due to the experimental level (*in vitro vs*. *in vivo*), where the induced tumors can be influenced by hormones floating in the bloodstream of the host organism. Overall, we anticipate that the linkage between androgen signaling and sarcosine metabolism may be vital for a development and progression of PCa and further research on this phenomenon may provide valuable information into the biology of these malicious diseases.

On the other hand, in PC-3 tumors, we have identified sarcosine-related up-regulation of *MAPK8* and *MAPK14*, which act as integration points for multiple biochemical signals and affect cellular processes, including proliferation \[[@pone.0165830.ref039]\]. Both *MAPK8* (encoding JNK1) and MAPK14 (encoding p38) signaling pathways are activated by pro- or anti-inflammatory cytokines, but also in response to cellular stress (genotoxic, osmotic, hypoxic or oxidative) to cause growth inhibition and apoptosis \[[@pone.0165830.ref040]\]. Contrary to that, it was also demonstrated that both JNK1 and p38 can act as PCa promoters. This depends on the cell type and specific stimuli inducing the ability to regulate cell adhesion, invasion and migration \[[@pone.0165830.ref041]\]. Considering all found results, it is obvious that sarcosine treatment did not exert significant antitumor action through up-regulation of *MAPK8* and *MAPK14*. Similar phenomenon has been identified in case of *p27* as the cyclin-dependent kinase inhibitor regulating cell proliferation, motility and apoptosis. Interestingly, it can exert both a positive and a negative action on these processes in dependence on diverse post-translation modifications \[[@pone.0165830.ref042]\]. We did not find any expression in non-treated LNCaP tumors; however sarcosine exposure resulted in a significant up-regulation of *p27*. Further studies on a protein level might be performed to investigate, whether the gene expression correlates with the protein amount and to elucidate, whether the protein translated in response to sarcosine presence, behaves as the good or the bad one. Overall, we show that sarcosine plays a pivotal role in influencing metastatic PCa cells, irrespective of androgen dependence status.

Conclusion {#sec024}
==========

The present study demonstrates that sarcosine treatment stimulates the PCa cells, both *in vitro* and *in vivo*. Our results indicate that direct, repeated administration to sarcosine has significant stimulatory effects on the growth of ectopic prostate tumors. Further biochemical and molecular-biology analyses revealed considerable impact of treatment on sarcosine metabolic pathway and the expression of genes involved in cell proliferation, cell cycle and apoptosis, which are the major hallmarks of each cancer. To the best of our knowledge, this is the first study showing the direct effects of repeated sarcosine treatment on an organism bearing prostate tumor. Despite the complexity of obtained data, there are still questions arising, including the impact of enzymatic activities of sarcosine metabolism enzymes on PCa development. Moreover, our results might be verified by a detailed proteomic screening. Despite those facts, the present study confirmed sarcosine as important PCa oncometabolite in both androgen dependent and androgen independent metastatic PCa cells, and provided pivotal information, which could be further investigated and developed.
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